Thoughts on the research of African swine fever live-attenuated vaccines

被引:1
|
作者
Chu, Xuefei [1 ]
Ge, Shengqiang [2 ,3 ,4 ]
Zuo, Yuanyuan [2 ]
Cui, Jin [2 ]
Sha, Zhou [2 ]
Han, Naijun [2 ]
Wu, Bingrong [1 ]
Ni, Bo [2 ]
Zhang, Hui [2 ]
Lv, Yan [2 ]
Wang, Zhiliang [2 ]
Xiao, Yihong [1 ]
机构
[1] Shandong Agr Univ, Coll Anim Sci & Technol, 61 Daizong St, Tai An 271018, Shandong Provin, Peoples R China
[2] China Anim Hlth & Epidemiol Ctr, 369 Nanjing Rd, Qingdao 266032, Peoples R China
[3] Qingdao Key Lab Modern Bioengn & Anim Dis Res, Qingdao 266032, Peoples R China
[4] Minist Agr & Rural Affairs, Key Lab Anim Biosafety Risk Warning Prevent & Cont, Qingdao 266032, Shandong, Peoples R China
关键词
Live attenuated vaccine; Gene-deficient vaccine strain; Immunization; Challenge protection; Safty; ISOLATE HARBORING DELETIONS; VIRULENCE-ASSOCIATED GENE; GEORGIA ISOLATE; PORCINE MACROPHAGES; DOMESTIC PIGS; VIRUS; PROTECTION; INFECTION; 9GL; EXPRESSION;
D O I
10.1016/j.vaccine.2024.06.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
African swine fever (ASF) is a contagious and fatal disease caused by the African swine fever virus (ASFV), which can infect pigs of all breeds and ages. Most infected pigs have poor prognosis, leading to substantial economic losses for the global pig industry. Therefore, it is imperative to develop a safe and efficient commercial vaccine against ASF. The development of ASF vaccine can be traced back to 1960. However, because of its large genome, numerous encoded proteins, and complex virus particle structure, currently, no effective commercial vaccine is available. Several strategies have been applied in vaccine design, some of which are potential candidates for vaccine development. This review provides a comprehensive analysis on the safety and effectiveness, suboptimal immunization effects at high doses, absence of standardized evaluation criteria, notable variations among strains of the same genotype, and the substantial impact of animal health on the protective efficacy against viral challenge. All the information will be helpful to the ASF vaccine development.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Genome Plasticity of African Swine Fever Virus: Implications for Diagnostics and Live-Attenuated Vaccines
    Faburay, Bonto
    PATHOGENS, 2022, 11 (02):
  • [2] Recent progress on gene-deleted live-attenuated African swine fever virus vaccines
    Vu, Hiep L. X.
    Mcvey, D. Scott
    NPJ VACCINES, 2024, 9 (01)
  • [3] Recent progress on gene-deleted live-attenuated African swine fever virus vaccines
    Hiep L. X. Vu
    D. Scott McVey
    npj Vaccines, 9
  • [4] Comparative Analysis of Swine Antibody Responses following Vaccination with Live-Attenuated and Killed African Swine Fever Virus Vaccines
    Luong, Hung Q.
    Lai, Huong T. L.
    Truong, Lam Q.
    Nguyen, The N.
    Vu, Hanh D.
    Nguyen, Hoa T.
    Nguyen, Lan T.
    Pham, Trang H.
    McVey, D. Scott
    Vu, Hiep L. X.
    VACCINES, 2023, 11 (11)
  • [5] Chimeric pestiviruses: candidates for live-attenuated classical swine fever marker vaccines
    Wehrle, Franziska
    Renzullo, Sandra
    Faust, Anja
    Beer, Martin
    Kaden, Volker
    Hofmann, Martin A.
    JOURNAL OF GENERAL VIROLOGY, 2007, 88 : 2247 - 2258
  • [6] Thoughts on African Swine Fever Vaccines
    Rock, Daniel L.
    VIRUSES-BASEL, 2021, 13 (05):
  • [7] Live-attenuated Shigella vaccines
    Venkatesan, Malabi M.
    Ranallo, Ryan T.
    EXPERT REVIEW OF VACCINES, 2006, 5 (05) : 669 - 686
  • [8] Research progress on live attenuated vaccine against African swine fever virus
    Liu, Le
    Wang, Xiangwei
    Mao, Ruoqing
    Zhou, Yahua
    Yin, Juanbin
    Sun, Yuefeng
    Yin, Xiangping
    MICROBIAL PATHOGENESIS, 2021, 158
  • [9] Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines
    Martinez-Sobrido, Luis
    de la Torre, Juan Carlos
    EXPERT REVIEW OF VACCINES, 2016, 15 (09) : 1113 - 1121
  • [10] Live-attenuated Yersinia pestis vaccines
    Wang, Xiaoyi
    Zhang, Xuecan
    Zhou, Dongsheng
    Yang, Ruifu
    EXPERT REVIEW OF VACCINES, 2013, 12 (06) : 677 - 686